172 related articles for article (PubMed ID: 34369053)
21. Clinical Trial Design Innovations for Precision Medicine in Asthma.
Siddiqui S; Haf Davies E; Afshar M; Denlinger LC
Adv Exp Med Biol; 2023; 1426():395-412. PubMed ID: 37464130
[TBL] [Abstract][Full Text] [Related]
22. Challenges and opportunities in biomarker-driven trials: adaptive randomization.
Park Y
Ann Transl Med; 2022 Sep; 10(18):1035. PubMed ID: 36267794
[TBL] [Abstract][Full Text] [Related]
23. A subgroup cluster-based Bayesian adaptive design for precision medicine.
Guo W; Ji Y; Catenacci DVT
Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
[TBL] [Abstract][Full Text] [Related]
24. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
Gao Z; Roy A; Tan M
Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
[TBL] [Abstract][Full Text] [Related]
25. A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.
Zhang Z; Ma S; Nie L; Soon G
Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28343164
[TBL] [Abstract][Full Text] [Related]
26. New clinical trial design in precision medicine: discovery, development and direction.
Duan XP; Qin BD; Jiao XD; Liu K; Wang Z; Zang YS
Signal Transduct Target Ther; 2024 Mar; 9(1):57. PubMed ID: 38438349
[TBL] [Abstract][Full Text] [Related]
27. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing prognostic and predictive biomarkers: an information theoretic approach.
Sechidis K; Papangelou K; Metcalfe PD; Svensson D; Weatherall J; Brown G
Bioinformatics; 2018 Oct; 34(19):3365-3376. PubMed ID: 29726967
[TBL] [Abstract][Full Text] [Related]
29. Study designs for clinical trials applied to personalised medicine: a scoping review.
Superchi C; Brion Bouvier F; Gerardi C; Carmona M; San Miguel L; Sánchez-Gómez LM; Imaz-Iglesia I; Garcia P; Demotes J; Banzi R; Porcher R;
BMJ Open; 2022 May; 12(5):e052926. PubMed ID: 35523482
[TBL] [Abstract][Full Text] [Related]
30. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
[TBL] [Abstract][Full Text] [Related]
31. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers and Precision Medicine: State of the Art.
Sarma A; Calfee CS; Ware LB
Crit Care Clin; 2020 Jan; 36(1):155-165. PubMed ID: 31733677
[TBL] [Abstract][Full Text] [Related]
33. Statistical issues and advances in cancer precision medicine research.
Nasution MD; Wang X
J Biopharm Stat; 2018; 28(2):215-216. PubMed ID: 29513634
[No Abstract] [Full Text] [Related]
34. Clinical trial designs incorporating predictive biomarkers.
Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
[TBL] [Abstract][Full Text] [Related]
35. Personalized medicine using DNA biomarkers: a review.
Ziegler A; Koch A; Krockenberger K; Grosshennig A
Hum Genet; 2012 Oct; 131(10):1627-38. PubMed ID: 22752797
[TBL] [Abstract][Full Text] [Related]
36. Covariate-adjusted response-adaptive designs for longitudinal treatment responses: PEMF trial revisited.
Biswas A; Park E; Bhattacharya R
Stat Methods Med Res; 2012 Aug; 21(4):379-92. PubMed ID: 20974667
[TBL] [Abstract][Full Text] [Related]
37. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine.
Dunn G; Emsley R; Liu H; Landau S
Clin Trials; 2013 Oct; 10(5):709-19. PubMed ID: 24000376
[TBL] [Abstract][Full Text] [Related]
38. Multi-arm covariate-adaptive randomization.
Hu F; Ye X; Zhang LX
Sci China Math; 2023; 66(1):163-190. PubMed ID: 35912316
[TBL] [Abstract][Full Text] [Related]
39. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.
Shi Q; Mandrekar SJ; Sargent DJ
Scand J Gastroenterol; 2012 Mar; 47(3):356-62. PubMed ID: 22181041
[TBL] [Abstract][Full Text] [Related]
40. Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine.
Rahman R
Cancer J; 2021 Sep-Oct 01; 27(5):410-415. PubMed ID: 34570456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
